Skip to main content
. Author manuscript; available in PMC: 2024 Dec 5.
Published in final edited form as: Int J Biochem Cell Biol. 2022 Mar 7;145:106191. doi: 10.1016/j.biocel.2022.106191

Table 3. Drugs targeting Wnt antagonist in other pathophysiological conditions.

Antagonist Model Used Drug Mechansim Phase of Clinical trial Status Reference
DKK1 Ovotoxic mice Letrozole Increase DKK1 in estrogen deficient mice in both lumbar and femur bones – (Kalam et al., 2017)
SOST Ovotoxic mice Letrozole increase SOST in estrogen deficienct mice in both lumbar and femur bones – (Kalam et al., 2017)
DrugBank Romosozumab Inhibitor – (Wishart et al., 2018)
IGFBP-4 DrugBank Mecasermin Carrier – (Wishart et al., 2018)
5T4 (Waif1/ 5T4) Colorectal, renal and prostate cancer patients MVA-5T4 Antibody; Vaccine III; II (22409460; 01556841) (Amato and Stepankiw, 2012)
SFRP1 PubChem 5-(benzenesulfonyl)-N-[3-(dimethylamino) propyl]–2-ethylbenzenesulfonamide Inhibitor (Kim et al., 2021)
SFRP4 DrugBank Cyclothiazide Inhibitor – (Wishart et al., 2018)